Hypertension

>

Latest News

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor
Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

January 17th 2025

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Mobile App Shows Promise for Hypertension Management: Daily Dose / image credit: ©New Africa/AdobeStock
Mobile App Shows Promise for Hypertension Management: Daily Dose

January 9th 2025

Smartphone App Shows Promise for Managing Hypertension in Observational Study / Image credit: ©ra2 studio/AdobeStock
Smartphone App Shows Promise for Managing Hypertension in Observational Study

December 20th 2024

New Trial Backs Intensive Blood Pressure Target for Adults with T2D: Daily Dose / image credit: ©New Africa/AdobeStock
New Trial Backs Intensive Blood Pressure Target for Adults with T2D: Daily Dose

December 2nd 2024

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes / image credit ©Yi Zhang
Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

November 18th 2024

<1
...
2526272829
© 2025 MJH Life Sciences

All rights reserved.